Lingohr & Partner Asset Management GmbH maintained its position in shares of Mylan N.V. (NASDAQ:MYL) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,879 shares of the company’s stock at the end of the 2nd quarter. Lingohr & Partner Asset Management GmbH’s holdings in Mylan N.V. were worth $853,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of MYL. Global X Management Co. LLC boosted its stake in Mylan N.V. by 91.6% during the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after purchasing an additional 1,441 shares during the last quarter. TLP Group LLC purchased a new stake in Mylan N.V. during the 1st quarter valued at $200,000. Eagle Global Advisors LLC purchased a new stake in Mylan N.V. during the 2nd quarter valued at $205,000. Sheaff Brock Investment Advisors LLC purchased a new stake in Mylan N.V. during the 2nd quarter valued at $210,000. Finally, Clear Harbor Asset Management LLC purchased a new stake in Mylan N.V. during the 2nd quarter valued at $215,000. Institutional investors own 71.97% of the company’s stock.
Shares of Mylan N.V. (NASDAQ MYL) traded down 2.56% during midday trading on Friday, reaching $32.03. The company’s stock had a trading volume of 20,184,738 shares. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The firm has a market capitalization of $17.18 billion, a P/E ratio of 25.89 and a beta of 1.31. The stock has a 50-day moving average of $32.33 and a 200 day moving average of $37.58.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. During the same quarter last year, the company earned $1.16 EPS. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. Equities research analysts predict that Mylan N.V. will post $4.52 EPS for the current fiscal year.
Several brokerages have commented on MYL. Cowen and Company reiterated a “hold” rating and set a $30.00 target price (down from $43.00) on shares of Mylan N.V. in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $32.00 target price (down from $33.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. Citigroup Inc. upgraded Mylan N.V. from a “neutral” rating to a “buy” rating and increased their target price for the company from $36.00 to $42.00 in a research note on Wednesday, August 16th. Wells Fargo & Company set a $30.00 target price on Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $34.00 target price on Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Mylan N.V. currently has a consensus rating of “Hold” and a consensus price target of $43.43.
TRADEMARK VIOLATION NOTICE: “Lingohr & Partner Asset Management GmbH Maintains Stake in Mylan N.V. (MYL)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://transcriptdaily.com/2017/09/17/lingohr-partner-asset-management-gmbh-maintains-stake-in-mylan-n-v-myl.html.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.